UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8–K
Current Report Filed Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported): May 8, 2002
Enchira Biotechnology Corporation
(Exact name of registrant as specified in its charter)
Delaware |
| 0-21130 |
| 04-3078857 |
(State or other jurisdiction of incorporation or organization) |
| (Commission File Number) |
| (I.R.S. Employer Identification No.) |
4200 Research Forest Drive
The Woodlands, Texas 77381
(Address of principal executive offices and zip code)
(281) 419-7000
(Registrant’s telephone number,
including area code)
Item 5. Other Events
On May 8, 2002, Enchira Biotechnology Corporation (the “Company”) issued a press release announcing that Howard, Frazier, Barker & Elliott has been engaged to review strategic alternatives for redeploying the Company’s assets, and in addition, the Company announced that it has reduced its headcount to the minimum necessary for such redeployment, retaining two officers, Daniel J. Monticello and Paul G. Brown, III, to complete its redeployment efforts. Paul Brown has been elected to President to replace Dr. Peter P. Policastro, who resigned as President and CEO and from the Board. Virtually all of the Company’s other officers and employees have resigned or been released. In addition, R. James Comeaux also recently announced his resignation from the Company’s Board of Directors.
The press release is filed as an exhibit to this Current Report on Form 8-K and is incorporated by reference herein.
Item 7. Exhibits
Exhibit 99.1 — Press Release
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Enchira Biotechnology Corporation | |
Date: May 8, 2002. |
| |
| By: | /s/ Paul G. Brown, III |
|
| Paul G. Brown, III |
|
| President |
3
